Forecast Parkinson Disease Progression to Better Select Patients into Trials

Juliette Ortholand, Etienne Maheux, Igor Koval, Arnaud Valladier, Stanley Durrleman

To cite this version:

Juliette Ortholand, Etienne Maheux, Igor Koval, Arnaud Valladier, Stanley Durrleman. Forecast Parkinson Disease Progression to Better Select Patients into Trials. AD/PD 2021 - 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, Mar 2021, Online, France. hal-03145333

HAL Id: hal-03145333

https://hal.archives-ouvertes.fr/hal-03145333

Submitted on 22 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
FORECAST PARKINSON DISEASE PROGRESSION TO BETTER SELECT PATIENTS INTO TRIALS

Juliette ORTHOLAND1, Etienne MAHEUX1, Igor KOVAL1, Arnaud VALLADIER1, Stanley DURRLEMAN1.
1 Inria, Aramis project-team, Institut du Cerveau et de la Moelle épinière, ICM, Inserm U 1127, CNRS UMR 7225, Sorbonne Université, F-75013, Paris, France

Objectives Subject recruitement is a burden that hampers clinical trials, especially in neurodegenerative diseases inducing long-term and subtle worsening of abilities. Better selecting them allows to reduce their required number - or conversely to improve the proven effect size.

Methods We extracted one-year separated visits in PPMI to model the placebo arm. For each patient, we derive a treated counterpart by applying an individual treatment effect calibrated so to get an effect size that correspond to a 4 point MDS-UPDRS II + III improvement and from which we derive a required sample size. Then, thanks to individual outcome predictions [Schiratti et al, 201] from which we derive a individual ratio of MDS-UPDRS II + III change, we select a subset of patients that minimizes the sample size for the previous effect size. The optimal ratio value is estimated on 80% of the PPMI patients and tested on the last 20%. We then test this ratio on DIGPD. The operations are bootstrapped 100 times on 50% of the data.

Results By selecting patients whose one-year MDS-UPDRS II+III ratio of predicted change is of 0.078 and for 0.4 of effect size, the number of patients needed to show a 0.4 effect size is reduced by 45±(11.4)SD% (resp. 55±(7.6)SD%) on the test set (resp. DIGPD evaluation).

Conclusions The use of our prediction model can concretly improve clinical trials on Parkinson’s disease by helping to better select patients and thus reduce the cohort size for a fixed treatment effect size.

References


Acknowledgments

The research leading to these results has received funding from the program "Investissements d’avenir" ANR-10-IAIHEU-06. This work was funded in part by the French government under management of Agence Nationale de la Recherche as part of the "Investissements d’avenir" program, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute).